Seroprevalence and risk factor for hepatitis C in Nogales, Sonora

Authors

  • Jesús Antonio Pérez-Mercado <p>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 5, Coordinaci&oacute;n Cl&iacute;nica de Educaci&oacute;n e Investigaci&oacute;n. Nogales, Sonora, M&eacute;xico.</p> http://orcid.org/0009-0001-9459-0384
  • Diana Lizeth Gallegos-Durazo <p>Instituto Mexicano del Seguro Social, Hospital General de Zona con Medicina Familiar No. 23, Unidad de Vigilancia Epidemiol&oacute;gica Hospitalaria. Parral, Chihuahua, M&eacute;xico.</p> http://orcid.org/0009-0001-8761-9564
  • Jorge Rafael Hernández-Donnadieu <p>Instituto Mexicano del Seguro Social, &Oacute;rgano de Operaci&oacute;n Administrativa Desconcentrado en Sonora, Coordinaci&oacute;n Auxiliar de Investigaci&oacute;n en Salud. Ciudad Obreg&oacute;n, Sonora, M&eacute;xico.</p> http://orcid.org/0000-0002-9646-0858
  • Edgar Daniel Copado-Villagrana <p>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 5, Unidad de Vigilancia Epidemiol&oacute;gica. Nogales, Sonora, M&eacute;xico.</p> http://orcid.org/0000-0002-6265-0485

DOI:

https://doi.org/10.5281/zenodo.11397093

Keywords:

Risk Factors, Seroepidemiologic Studies, Intranasal Drug Administrations, Hepatitis C

Abstract

Background: Hepatitis C Virus (HCV) infection represents a global public health problem, but in Mexico, the Ministry of Health through the National Epidemiological Surveillance System (SINAVE) only reports the distribution of incident cases by state, sex and epidemiological week.

Objective: To determine the seroprevalence and factors associated with HCV in beneficiaries of a Family Medicine Unit of the Mexican Social Security Institute (IMSS) in the city of Nogales, Sonora, located on the border between Mexico and the United States.

Material and methods: Cross-sectional study that included 145 beneficiaries with rapid HCV antibody test results. Information on risk factors was obtained through direct questioning. To compare groups of reactive and non-reactive patients, Fisher›s Exact Test was used and a Logistic Regression model to determine Odds Ratio (OR) values. A p value < 0.05 was considered statistically significant.

Results: A seroprevalence of 2.8% (95%CI: 0.8-6.9) was determined and through the logistic regression model it was found that the history of transfusions (OR: 151.2, 95%CI: 5.9-3.858.0) and the use of intranasal drugs (OR: 20.81, 95% CI: 1.3-331.3) increase the risk of infection.

Conclusions: The seroprevalence of HCV in Nogales is higher than that of the rest of Mexico. Recent studies establish a history of transfusion as a risk factor, but few have explored intranasal drug use.

Downloads

Download data is not yet available.

Author Biographies

  • Jesús Antonio Pérez-Mercado, <p>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 5, Coordinaci&oacute;n Cl&iacute;nica de Educaci&oacute;n e Investigaci&oacute;n. Nogales, Sonora, M&eacute;xico.</p>

    Médico Residente de Tercer año de la Especialidad en Epidemiología del Hospital General de Zona N° 5 en Nogales, Sonora. 

  • Diana Lizeth Gallegos-Durazo, <p>Instituto Mexicano del Seguro Social, Hospital General de Zona con Medicina Familiar No. 23, Unidad de Vigilancia Epidemiol&oacute;gica Hospitalaria. Parral, Chihuahua, M&eacute;xico.</p>

    Médico No Familiar Epidemiólogo, adscrito al Hospital General de Zona con Medicina Familiar N° 23 en Parral, Chihuahua. 

  • Jorge Rafael Hernández-Donnadieu, <p>Instituto Mexicano del Seguro Social, &Oacute;rgano de Operaci&oacute;n Administrativa Desconcentrado en Sonora, Coordinaci&oacute;n Auxiliar de Investigaci&oacute;n en Salud. Ciudad Obreg&oacute;n, Sonora, M&eacute;xico.</p>

    Coordinador Auxiliar Médico de Investigación en Salud del Órgano de Operación Administrativa Desconcentrado en Sonora del IMSS

  • Edgar Daniel Copado-Villagrana, <p>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 5, Unidad de Vigilancia Epidemiol&oacute;gica. Nogales, Sonora, M&eacute;xico.</p>

    Médico No Familiar Epidemiólogo, adscrito a la Unidad de Medicina Familiar N° 5 en Nogales, Sonora. Calificado como Candidato a Investigador Nacional por el Sistema Nacional de Investigadoras e Investigadores, Calificación Curricular como Investigador Clínico Asociado A ante el IMSS 

References

 Taha G, Ezra L, Abu-Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023. Viruses. 2023;15(7):1413. Disponible en: https://doi.org/10.3390/v15071413.

Organización Mundial de la Salud. Hepatitis C. Ginebra: OMS; 18 de Julio de 2023. Disponible en: https://www.who. int/news-room/fact-sheets/detail/hepatitis-c.

Organización Mundial de la Salud. Estrategias mundiales del sector de la salud contra el VIH, las hepatitis víricas y las infecciones de transmisión sexual para el periodo 2022-2030. Ginebra: OMS; 18 de julio de 2022. Disponible en: https:// www.who.int/publications/i/item/9789240053779.

Centro Nacional para la Prevención y Control del VIH y el SIDA. Programa de Acción Específico Virus de Hepatitis C. Ciudad de México: CENSIDA; 05 de abril de 2021. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/626762/ Programa_de_Acci_n_Espec_fico_VHC2020-2024.pdf.

De la Torre Rosas A, Kershenobich D, Svarch AE, et al. Eliminating Hepatitis C in Mexico: A Primary Health Care Approach. Clin Liver Dis (Hoboken). 2021;18(5):219-224. Disponible en: https://doi.org/10.1002/cld.1180.

Martínez-Bohorquez MC, Carnalla M, Chávez-Tapia N, et al. Hepatitis C mortality trends in Mexico from 2001 to 2017. Ann Hepatol. 2023 May-Jun;28(3):101083. doi: 10.1016/j.aohep. 2023.101083.

Ascencio-Montiel IJ. Hepatitis C in the three main health institutions in Mexico: a 13-year mortality and hospitalization analysis. Rev Inst Med Trop Sao Paulo. 2020 7;62:e11. doi: 10.1590/S1678-9946202062011.

Diario Oficial de la Federación. NORMA Oficial Mexicana NOM-017-SSA2-2012, Para la vigilancia epidemiológica. Ciudad de México: DOF; 19 de febrero de 2013. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5288225&fecha= 19/02/2013#gsc.tab=0.

Dirección General de Epidemiología. Boletín Epidemiológico Sistema Nacional de Vigilancia Epidemiológica Sistema Único de Información. Ciudad de México: DGE; 09 de enero de 2024. Disponible en: https://www.gob.mx/salud/documentos/ boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-261547.

Torres-Díaz JA, Jasso-Baltazar EA, Toapanta-Yanchapaxi L, et al. Hepatitis C virus-positive donors in HCV-negative recipients in liver transplantation: Is it possible in Mexico? Rev Gastroenterol Mex (Engl Ed). 2023;88(4):392-403. doi: 10.1016/j. rgmxen.2023.08.002.

Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero-Martínez M, Hernández-Ávila M. Disminución de la seroprevalencia de hepatitis C en México: resultados de la Ensanut 2012. Salud Publica Mex. 2016;58(1):25-32.

Carnalla M, Barrientos-Gutiérrez T, Vidaña-Perez D, et al. Prevalence of hepatitis C in the adult Mexican population: National Survey of Health and Nutrition 2018. Lancet Reg Health Am. 2021;8:100165. Disponible en https://doi.org/10.1016/j. lana.2021.100165.

Campollo O, Amaya G, McCormick PA. Milestones in the discovery of hepatitis C. World J Gastroenterol. 2022;28(37):5395- 5402. doi: 10.3748/wjg.v28.i37.5395.

Abu-Freha N, Mathew Jacob B, Elhoashla A, et al. Chronic hepatitis C: Diagnosis and treatment made easy. Eur J Gen Pract. 2022;28(1):102-108. Disponible en: https://doi.org/10.1 080/13814788.2022.2056161.

Liu CH, Kao JH. Acute hepatitis C virus infection: clinical update and remaining challenges. Clin Mol Hepatol. 2023;29(3):623- 642. Disponible en: https://doi.org/10.3350/cmh.2022.0349.

Fill MA, Sizemore LA, Rickles M, et al. Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. Epidemiol Infect. 2018;146(4):508-514. Disponible en: https://doi.org/10.1017/S0950268818000080.

McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003;35(4):455-60. Disponible en: https://doi.org/10.1111/ j.1478-3231.2008.01688.x.

Márquez LK, Borquez A, Fleiz C, et al. Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic. Gac Med Mex. 2022;158(2):110-113. doi: 10.24875/ GMM.M22000650.

Sánchez-Herrera D, Mellado-Orellana R, Rodríguez-Aguilar EF. Hepatitis C en usuarios de drogas inyectables en México: una visión general. Med Int Méx 2022;38(4):859-867.

Instituto Nacional de Salud Pública. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco (ENCODAT 2016). Ciudad de México: INSP; 29 de agosto de 2020. Disponible en: https://www.insp.mx/avisos/4585-encodat-2016.html.

Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334(26):1691-6. Disponible en https://doi.org/10.1056/NEJM199606273342602.

Fernandez N, Towers CV, Wolfe L, et al. Sharing of Snorting Straws and Hepatitis C Virus Infection in Pregnant Women. Obstet Gynecol. 2016;128(2):234-237. Disponible en: https:// doi.org/10.1097/AOG.0000000000001507.

Koblin BA, Factor SH, Wu Y, et al. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol. 2003;70(3):387-90. Disponible en https://doi.org/10.1002/ jmv.10407.

Simmons AE, Fiedler AI, Fisman DN, et al. The Association Between Self-Reported Non-Injection Cocaine Use and Hepatitis C in the United States: An Analysis of the National Health and Nutrition Examination Survey. J Stud Alcohol Drugs. 2022;83(2):195-201.

Wang CW, Chuang HY, Chiang HC, et al. Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy. J Chin Med Assoc. 2020;83(5):454- 460. doi: 10.1097/JCMA.0000000000000312.

Knick T, Sherbuk JE, Dillingham R. Knowledge of Hepatitis C Risk Factors is Lower in High Incidence Regions. J Community Health. 2019;44(1):12-15. doi: 10.1007/s10900-018-0545-6.

Novelo-Garza B, Duque-Rodríguez J, Mejía-Domínguez AM, et al. Blood safety in Mexico and a perspective on Latin America. Transfus Apher Sci. 2019;58(6):102661. doi: 10.1016/j. transci.2019.10.003.

Baliashvili D, Averhoff F, Kasradze A, et al. Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey. PLoS One. 2022;17(1):e0262935. Disponible en https://doi.org/10.1371/journal.pone.0262935.

Mohd Suan MA, Said SM, Lim PY, et al. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study. PLoS One. 2019;14(10):e0224459. Disponible en https://doi.org/10.1371/journal.pone.0224459.

Sosa-Jurado F, Palencia-Lara R, Xicoténcatl-Grijalva C, et al. Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico. Viruses. 2023; 15(6):1331. doi: 10.3390/v15061331.

Downloads

Published

2024-07-18

Issue

Vol. 62 No. 4 (2024): July-August

Section

Original Articles

License

Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.